Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00969709 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
A Phase 3 study of Major Depressive Disorder, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 724
- Enrollment target
- 20
- Study locations
NCT00969709 is a Phase 3 study of Major Depressive Disorder that has completed, run by Forest Laboratories. The registered enrollment target is 724 participants, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (94% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT00969709, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 724 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Levomilnacipran ER
Study Locations (20)
Florida
- Forest Investigative Site - Coral Springs
- Forest Investigative Site - Fort Myers
- Forest Investigative Site - Hallandale
- Forest Investigative Site - Jacksonville
- Forest Investigative Site - Orlando
- Forest Investigative Site - West Palm Beach
California
- Forest Investigative Site - Beverly Hills
- Forest Investigative Site - Costa Mesa
- Forest Investigative Site - Escondido
- Forest Investigative Site - Oceanside
- Forest Investigative Site - Sherman Oaks
Arizona
- Forest Investigative Site - Phoenix
- Forest Investigative Site - Scottsdale
Maryland
- Forest Investigative Site - Baltimore
- Forest Investigative Site - Rockville
Colorado
- Forest Investigative Site - Denver
Connecticut
- Forest Investigative Site - Cromwell
Illinois
- Forest Investigative Site - Hoffman Estates
Kansas
- Forest Investigative Site - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 724 participants |
| Start Date | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00969709
The ClinicalTrials.gov registry entry for NCT00969709 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 724 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 374-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (94% higher). The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00969709 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00969709 about?
NCT00969709 is a clinical study titled "Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder". The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
What is the current status of trial NCT00969709?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 724 participants. The study started on 2009-09.
What conditions does trial NCT00969709 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00969709?
The interventions under investigation include: Placebo (DRUG), Levomilnacipran ER (DRUG).
Who is sponsoring clinical trial NCT00969709?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00969709 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.